title: Tolerability of the COX-1/COX-2 inhibitor lornoxicam in the treatment of acute and rheumatic pain.
abstract: OBJECTIVE
  To assess the safety of lornoxicam with particular focus on gastrointestinal (GI) events.
  
  
  METHODS
  Data on adverse drug reactions (ADRs) were pooled from 60 comparative studies of lornoxicam.
  
  
  RESULTS
  A total of 6420 patients received lornoxicam, 1192 received placebo and 3770 received a comparator analgesic. ADRs were reported by 21% of lornoxicam-treated patients, with GI events the most frequent (14 vs 8% with placebo). Across 15 studies that compared lornoxicam (n = 1287) with another NSAID (n = 1010), there was a reduced risk of a GI ADR with lornoxicam (0.78 [95% CI: 0.64-0.96]; p = 0.017).
  
  
  CONCLUSIONS
  Lornoxicam was well tolerated with the type of GI events observed consistent with the known safety profile of NSAIDs.
authors.affiliation: Central University of Venezuela, Caracas, Venezuela.
authors.forename: Luis
authors.initials: L
authors.lastname: Parada
authors.affiliation: Takeda Pharmaceuticals International GmbH, Zurich, Switzerland.
authors.forename: Jens Pauli
authors.initials: JP
authors.lastname: Marstein
authors.affiliation: IM Sechenov First Moscow State Medical University, Moscow, Russia.
authors.forename: Andrey
authors.initials: A
authors.lastname: Danilov
mesh_terms: D000328:Adult; D001172:Arthritis, Rheumatoid / Q000150:complications*; D002986:Clinical Trials as Topic; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000209:etiology; D010894:Piroxicam / Q000009:adverse effects / Q000031:analogs & derivatives*; D016896:Treatment Outcome
chemical_list: D016861:Cyclooxygenase Inhibitors; D010894:Piroxicam; C059451:lornoxicam
keywords: COX inhibitors; NSAIDs; acute pain; gastrointestinal toxicity; lornoxicam; oxicams; rheumatic pain